2023
Bacillus Calmette–Guérin Vaccine Attenuates Haloperidol-Induced TD-like Behavioral and Neurochemical Alteration in Experimental Rats
Yedke N, Upadhayay S, Singh R, Jamwal S, Ahmad S, Kumar P. Bacillus Calmette–Guérin Vaccine Attenuates Haloperidol-Induced TD-like Behavioral and Neurochemical Alteration in Experimental Rats. Biomolecules 2023, 13: 1667. PMID: 38002349, PMCID: PMC10669047, DOI: 10.3390/biom13111667.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntipsychotic AgentsBCG VaccineBehavior, AnimalHaloperidolRatsTardive DyskinesiaConceptsBCG vaccineTardive dyskinesiaOrofacial dyskinesiaNeurotransmitter levelsBacillus Calmette-Guérin (BCG) vaccineFirst-generation antipsychotic drugsManagement of TDOxidative stressLevels of HVACalmette-Guérin vaccineHyperkinetic movement disordersMajor pathophysiological mechanismsPro-apoptotic markersLong-term useBCG treatmentNeuroprotective effectsNeurochemical alterationsOrofacial dysfunctionPathophysiological mechanismsAntipsychotic medicationNeuromodulatory propertiesSuppress inflammationSingle administrationAntipsychotic drugsHaloperidol injectionAge-associated sex difference in the expression of mitochondria-based redox sensitive proteins and effect of pioglitazone in nonhuman primate brain
Jamwal S, Blackburn J, Elsworth J. Age-associated sex difference in the expression of mitochondria-based redox sensitive proteins and effect of pioglitazone in nonhuman primate brain. Biology Of Sex Differences 2023, 14: 65. PMID: 37770961, PMCID: PMC10540392, DOI: 10.1186/s13293-023-00551-6.Peer-Reviewed Original ResearchConceptsSubstantia nigraSex-dependent expressionPrimate brainAdult male monkeysCerebrospinal fluidMale monkeysPeroxisome proliferator-activated receptor gamma agonistProliferator-activated receptor gamma agonistsEffect of pioglitazoneWeeks of treatmentReceptor gamma agonistsGreater expressionAdult female monkeysNonhuman primate brainNovel neuroprotective treatmentAfrican green monkeysSex-based differencesOral pioglitazoneNeuroprotective treatmentPIO treatmentRisk factorsCNS disordersGamma agonistsPreclinical studiesParkinson's diseaseAnimal models of Huntington’s disease and their applicability to novel drug discovery and development
Upadhayay S, Jamwal S, Kumar P. Animal models of Huntington’s disease and their applicability to novel drug discovery and development. Expert Opinion On Drug Discovery 2023, 18: 527-538. PMID: 37042034, DOI: 10.1080/17460441.2023.2201493.Peer-Reviewed Original ResearchConceptsHD animal modelsAnimal modelsHuntington's diseaseNon-motor symptomsProgressive neurodegenerative disorderDrug therapyDisease progressionPreclinical phaseLoss of functionNeurodegenerative disordersClinical phaseDrug discoveryDiseaseNovel drug discoveryHuntingtin geneToxic gainCAG trinucleotide repeatDrugsProgressionHD geneEnormous progressionAn Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington's Disease Model and Its Relevance to Drug Discovery and Development
Upadhayay S, Yedke N, Rahi V, Singh S, Kumar S, Arora A, Chandolia P, Kaur P, Kumar M, Koshal P, Jamwal S, Kumar P. An Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington's Disease Model and Its Relevance to Drug Discovery and Development. Neurochemical Research 2023, 48: 1631-1647. PMID: 36738367, DOI: 10.1007/s11064-023-03868-1.Peer-Reviewed Original ResearchConceptsMedium spiny neuronsAnimal modelsGABAergic medium spiny neuronsDisease modelsKey clinical manifestationsHuntington's disease modelsPathogenesis of diseaseWeb of ScienceClinical manifestationsPathophysiological mechanismsSpiny neuronsPreclinical studiesMotor impairmentLike symptomsTherapeutic targetExperimental animalsExcessive productionHuntington's diseaseOxidative stressDiseasePathogenic conditionsDrug discoveryMitochondrial functionFree radicalsNeurotoxin
2021
Expression of PON2 isoforms varies among brain regions in male and female African green monkeys
Jamwal S, Blackburn JK, Elsworth JD. Expression of PON2 isoforms varies among brain regions in male and female African green monkeys. Free Radical Biology And Medicine 2021, 178: 215-218. PMID: 34890766, PMCID: PMC8760629, DOI: 10.1016/j.freeradbiomed.2021.12.005.Peer-Reviewed Original ResearchConceptsAfrican green monkeysParkinson's diseaseBrain regionsParaoxonase 2Different brain regionsFemale monkeysGreen monkeysPON2 expressionOxidative stress-related neurodegenerative disordersFemale African green monkeysNeurodegenerative disordersMale African green monkeysOxidative stressPON2 protein expressionAnti-inflammatory propertiesExpression levelsSignificant differencesBrain tissue samplesDorsolateral prefrontal cortexNeuroprotective strategiesWestern blotting techniquesDopaminergic neuronsPON2 proteinPrimate brainProtective rolePioglitazone transiently stimulates paraoxonase-2 expression in male nonhuman primate brain: Implications for sex-specific therapeutics in neurodegenerative disorders
Blackburn JK, Jamwal S, Wang W, Elsworth JD. Pioglitazone transiently stimulates paraoxonase-2 expression in male nonhuman primate brain: Implications for sex-specific therapeutics in neurodegenerative disorders. Neurochemistry International 2021, 152: 105222. PMID: 34767873, PMCID: PMC8712400, DOI: 10.1016/j.neuint.2021.105222.Peer-Reviewed Original ResearchConceptsPON2 expressionParkinson's diseaseParaoxonase 2Male African green monkeysShort-term animal modelsOxidative stressPeroxisome proliferator-activated receptor gammaEffect of pioglitazoneWeeks of treatmentProliferator-activated receptor gammaNonhuman primate brainParaoxonase-2 expressionRegion-dependent expressionSex-specific therapeuticsAnti-diabetic drug pioglitazoneAfrican green monkeysDorsolateral prefrontal cortexOral pioglitazonePreclinical evidenceSubstantia nigraClinical trialsPON2 mRNAAnimal modelsPioglitazonePrimate brainSex-based disparity in paraoxonase-2 expression in the brains of African green monkeys
Jamwal S, Blackburn JK, Elsworth JD. Sex-based disparity in paraoxonase-2 expression in the brains of African green monkeys. Free Radical Biology And Medicine 2021, 167: 201-204. PMID: 33722626, PMCID: PMC8096713, DOI: 10.1016/j.freeradbiomed.2021.03.003.Peer-Reviewed Original ResearchConceptsAfrican green monkeysParaoxonase 2Parkinson's diseaseBrain regionsGreen monkeysOxidative stressReactive oxygen speciesAnti-inflammatory propertiesSex-based disparitiesParaoxonase-2 expressionDifferent brain regionsNigrostriatal systemPON2 expressionDevelopment of therapeuticsNeurodegenerative disordersDiseaseProtein levelsROS levelsLower ROS levelsMitochondrial performanceSex-based variationDisordersMonkeysOxygen speciesMalesNeuroprotection through G-CSF: recent advances and future viewpoints
Rahi V, Jamwal S, Kumar P. Neuroprotection through G-CSF: recent advances and future viewpoints. Pharmacological Reports 2021, 73: 372-385. PMID: 33389706, DOI: 10.1007/s43440-020-00201-3.Peer-Reviewed Original ResearchConceptsGranulocyte-colony stimulating factorNeutrophilic granulocyte lineageNumerous cell typesJAK/STATG-CSF receptorPI3K/AktInhibition of apoptosisTransduction pathwaysHaemopoietic stem cellsMAP kinaseNeuronal differentiationHematopoietic stemCell typesGranulocyte lineageNeurological disordersStem cellsProgenitor cellsRecent pre-clinical studiesHematopoietic growth factorsAttractive targetChemotherapy-associated neutropeniaStimulation of neurogenesisObserved neuroprotective effectsDifferentiationPre-clinical studies
2020
Exploring the molecular approach of COX and LOX in Alzheimer’s and Parkinson’s disorder
Kumar A, Behl T, Jamwal S, Kaur I, Sood A, Kumar P. Exploring the molecular approach of COX and LOX in Alzheimer’s and Parkinson’s disorder. Molecular Biology Reports 2020, 47: 9895-9912. PMID: 33263931, DOI: 10.1007/s11033-020-06033-x.Peer-Reviewed Original ResearchConceptsParkinson's diseaseDocosahexaenoic acidAlzheimer's diseaseArachidonic acidLipid mediatorsAnti-inflammatory actionAppropriate therapeutic optionPro-inflammatory eicosanoidsProduction of eicosanoidsResolution of inflammationRole of AACOX-2 enzymeLOX pathwayNeuroinflammatory responseNeuroinflammatory eventsTherapeutic optionsAD patientsCytokine secretionEpidemiological studiesLeukocyte traffickingNF-κBEicosanoid productionBrain disordersNeurological disordersCyclooxygenaseGene therapy and immunotherapy as promising strategies to combat Huntington’s disease-associated neurodegeneration: emphasis on recent updates and future perspectives
Jamwal S, Elsworth JD, Rahi V, Kumar P. Gene therapy and immunotherapy as promising strategies to combat Huntington’s disease-associated neurodegeneration: emphasis on recent updates and future perspectives. Expert Review Of Neurotherapeutics 2020, 20: 1123-1141. PMID: 32720531, DOI: 10.1080/14737175.2020.1801424.Peer-Reviewed Original ResearchConceptsGene therapyClinical trialsDisease-modifying therapiesMutant huntingtinTreatment of HDAntibody-based therapiesPotential therapeutic interventionsNew therapeutic targetsGene-based therapiesImmune activationClinical dataImmunotherapyTherapeutic targetFunctional restorationTherapeutic interventionsTherapyHD pathogenesisMHTT proteinRecent updatesFuture perspectivesPromising strategyTrialsCurrent statusConsiderable attentionHDProtective Effect of Hemin Against Experimental Chronic Fatigue Syndrome in Mice: Possible Role of Neurotransmitters
Thakur V, Jamwal S, Kumar M, Rahi V, Kumar P. Protective Effect of Hemin Against Experimental Chronic Fatigue Syndrome in Mice: Possible Role of Neurotransmitters. Neurotoxicity Research 2020, 38: 359-369. PMID: 32506340, DOI: 10.1007/s12640-020-00231-y.Peer-Reviewed Original ResearchMeSH Keywords3,4-Dihydroxyphenylacetic AcidAnimalsAnxietyBehavior, AnimalBrainDisease Models, AnimalDopamineElectron Transport Complex IElectron Transport Complex IIElevated Plus Maze TestEnzyme InhibitorsFatigue Syndrome, ChronicGlutathioneHand StrengthHeme Oxygenase-1HeminHomovanillic AcidHydroxyindoleacetic AcidLipid PeroxidationLocomotionMetalloporphyrinsMiceMitochondriaNeurotransmitter AgentsNitritesNorepinephrineProtoporphyrinsSerotoninConceptsChronic fatigue syndromeMitochondrial complex dysfunctionFatigue syndromeProtective effectComplex dysfunctionMale albino miceAnxiety-like behaviorFatigue-like behaviorAntifatigue effectNeurotransmitter alterationsCommon symptomsPresent studyNeurotransmitter levelsSwimming testAlbino miceExperimental miceImmobility periodEnzyme inhibitorsProtective roleCognitive impairmentLocomotor activityBehavioral testsSwimming sessionBiochemical parametersBiochemical alterations
2019
Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson’s Disease and Huntington’s Disease: A Review
Jamwal S, Kumar P. Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson’s Disease and Huntington’s Disease: A Review. Current Neuropharmacology 2019, 17: 165-175. PMID: 29512464, PMCID: PMC6343208, DOI: 10.2174/1570159x16666180302115032.Peer-Reviewed Original ResearchConceptsParkinson's diseaseHuntington's diseaseStriatal neurotransmittersNeuronal deathNeurotransmitter levelsAltered neurotransmitters levelBasal ganglia regionsExcitotoxic neuronal deathNeurotransmitter alterationsBrain dopaminePathophysiological basisBasal gangliaGanglia regionsMovement disordersPreclinical studiesReceptor densitySpecific drugsCoordinated body movementsDiseaseNeurotransmittersAltered levelsOxidative stressExact mechanismMitochondrial dysfunctionImportant neurotransmitter
2017
Glucagon-like Peptide-1 (GLP-1) and neurotransmitters signaling in epilepsy: An insight review
Koshal P, Jamwal S, Kumar P. Glucagon-like Peptide-1 (GLP-1) and neurotransmitters signaling in epilepsy: An insight review. Neuropharmacology 2017, 136: 271-279. PMID: 29129776, DOI: 10.1016/j.neuropharm.2017.11.015.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1Neurotransmitter systemsAltered neurotransmittersProtective roleNeurological disordersNeurotransmitter signalingProgression of seizuresGABAergic neurotransmitter systemAnti-epileptic drugsManagement of epilepsyGLP-1 analoguesGLP-1 receptorTreatment of epilepsyFuture drug therapiesOnly symptomatic reliefBasic pathogenic mechanismsPrevalent neurological disordersPreproglucagon neuronsSymptomatic reliefGlutamatergic systemPathophysiological mechanismsDrug therapyRisk factorsMetabolic impairmentPeptide-1L-theanine prevent quinolinic acid induced motor deficit and striatal neurotoxicity: Reduction in oxido-nitrosative stress and restoration of striatal neurotransmitters level
Jamwal S, Singh S, Gill JS, Kumar P. L-theanine prevent quinolinic acid induced motor deficit and striatal neurotoxicity: Reduction in oxido-nitrosative stress and restoration of striatal neurotransmitters level. European Journal Of Pharmacology 2017, 811: 171-179. PMID: 28624333, DOI: 10.1016/j.ejphar.2017.06.016.Peer-Reviewed Original ResearchConceptsStriatal neurotransmitter levelsOxido-nitrosative stressNeurotransmitter levelsProtective effectL-NAMEMotor deficitsQuinolinic acidL-arginineL-theanineNitric oxide synthase inhibitorPro-inflammatory cytokinesNitric oxide pathwayOxide synthase inhibitorOpen field testL-theanine treatmentRota-rodBeam walkingNeuro-inflammationNeurotransmitter alterationsNeuroprotective potentialStriatal neurotoxicityOxide pathwayQA injectionGrip strengthMotor coordination
2016
Sertraline and venlafaxine improves motor performance and neurobehavioral deficit in quinolinic acid induced Huntington’s like symptoms in rats: Possible neurotransmitters modulation
Gill JS, Jamwal S, Kumar P, Deshmukh R. Sertraline and venlafaxine improves motor performance and neurobehavioral deficit in quinolinic acid induced Huntington’s like symptoms in rats: Possible neurotransmitters modulation. Pharmacological Reports 2016, 69: 306-313. PMID: 28178592, DOI: 10.1016/j.pharep.2016.11.008.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCorpus StriatumDisease Models, AnimalGamma-Aminobutyric AcidGlutamic AcidHuntington DiseaseInterleukin-1betaInterleukin-6Lipid PeroxidationMaleMotor ActivityNeuroprotective AgentsNeurotransmitter AgentsOxidative StressQuinolinic AcidRatsRats, WistarRotarod Performance TestSertralineTumor Necrosis Factor-alphaVenlafaxine HydrochlorideConceptsMotor performanceQuinolinic acidAvailable drugsPro-inflammatory cytokine levelsNumerous neuroprotective propertiesAnti-inflammatory propertiesGrip strength testProgressive neurodegenerative disorderBDNF levelsCytokine levelsSymptomatic reliefNeuroprotective effectsRotarod testMonoamine levelsNeuroprotective propertiesStriatal atrophyNeurobehavioral deficitsNeurotransmitter levelsNeurotransmitter modulationGlutamatergic signalingRat striatumNeurochemical analysisBody weightDay 22Neurochemical levelsL-theanine, a Component of Green Tea Prevents 3-Nitropropionic Acid (3-NP)-Induced Striatal Toxicity by Modulating Nitric Oxide Pathway
Jamwal S, Kumar P. L-theanine, a Component of Green Tea Prevents 3-Nitropropionic Acid (3-NP)-Induced Striatal Toxicity by Modulating Nitric Oxide Pathway. Molecular Neurobiology 2016, 54: 2327-2337. PMID: 26957301, DOI: 10.1007/s12035-016-9822-5.Peer-Reviewed Original ResearchConceptsHuntington's diseaseStriatal toxicityL-NAMENeuroprotective potentialConcurrent treatmentProtective effectBody weightL-arginineL-theanineGABAergic medium spiny neuronsGreen tea preventsStriatal neurotransmitter levelsPro-inflammatory mediatorsPro-inflammatory cytokinesNitric oxide pathwayBlood-brain barrierMedium spiny neuronsNitric oxide productionL-theanine treatmentNeurotransmitter alterationsOxide pathwayBrain barrierSpiny neuronsNeurotransmitter levelsRat striatum
2015
Beneficial effects of lycopene against haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation
Datta S, Jamwal S, Deshmukh R, Kumar P. Beneficial effects of lycopene against haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation. European Journal Of Pharmacology 2015, 771: 229-235. PMID: 26712377, DOI: 10.1016/j.ejphar.2015.12.032.Peer-Reviewed Original ResearchConceptsOrofacial dyskinesiaHaloperidol treatmentChronic neuroleptic treatmentAbnormal involuntary movementsSevere side effectsNeuroinflammatory modulationNeuroleptic treatmentTardive dyskinesiaProtective effectInvoluntary movementsSide effectsDyskinesiaBiochemical parametersHaloperidolRatsTreatmentDaysLycopeneStriatumSpermidine ameliorates 3-nitropropionic acid (3-NP)-induced striatal toxicity: Possible role of oxidative stress, neuroinflammation, and neurotransmitters
Jamwal S, Kumar P. Spermidine ameliorates 3-nitropropionic acid (3-NP)-induced striatal toxicity: Possible role of oxidative stress, neuroinflammation, and neurotransmitters. Physiology & Behavior 2015, 155: 180-187. PMID: 26703234, DOI: 10.1016/j.physbeh.2015.12.015.Peer-Reviewed Original ResearchConceptsHuntington's diseaseStriatal toxicityStriatal neurotransmittersRat striatumMotor coordinationPro-inflammatory cytokine levelsOxidative stressPro-inflammatory mediatorsPotential neuroprotective effectsAnti-inflammatory propertiesGood experimental modelConfer neuroprotectionCytokine levelsNeuroinflammatory markersNeuroprotective effectsPresent studyNeurochemical analysisBody weightTherapeutic potentialNeurodegenerative disordersBiochemical parametersExperimental modelDecreased levelsNeurotransmittersSignificant alterationsAntidepressants for neuroprotection in Huntington's disease: A review
Jamwal S, Kumar P. Antidepressants for neuroprotection in Huntington's disease: A review. European Journal Of Pharmacology 2015, 769: 33-42. PMID: 26511378, DOI: 10.1016/j.ejphar.2015.10.033.Peer-Reviewed Original ResearchConceptsHuntingtin proteinHuntington's diseaseMAPK/ERK signalingBrain-derived neurotrophic factor (BDNF) productionBDNF/TrkB pathwayProgression of HDDifferent neuroprotective mechanismsPrincipal neuropathological hallmarksUse of antidepressantsNeurotrophic factor productionCortical projection neuronsMutant huntingtin proteinCellular functionsPolyglutamine stretchMolecular mechanismsNH2 terminusERK signalingTrkB pathwayPreclinical evidenceNeuroprotective effectsNeuroprotective mechanismsCommon symptomsProjection neuronsAvailable treatmentsDisease progressionBeneficial effect of zinc chloride and zinc ionophore pyrithione on attenuated cardioprotective potential of preconditioning phenomenon in STZ-induced diabetic rat heart
Jamwal S, Kumar K, Reddy BV. Beneficial effect of zinc chloride and zinc ionophore pyrithione on attenuated cardioprotective potential of preconditioning phenomenon in STZ-induced diabetic rat heart. Perfusion 2015, 31: 334-342. PMID: 26423303, DOI: 10.1177/0267659115608935.Peer-Reviewed Original ResearchConceptsDiabetic rat heartsMyocardial infarct sizeCreatine kinase-MBZinc ionophore pyrithioneIschemic preconditioningNormal rat heartsCardioprotective potentialInfarct sizeRat heartMPO levelsDiabetes mellitusCoronary effluentLactate dehydrogenaseSTZ-induced diabetic rat heartIonophore pyrithioneGSK-3βPost-ischemic treatmentMinutes of reperfusionRelease of LDHMinutes of ischemiaTriphenyltetrazolium chloride stainingGSK-3β levelsSingle intraperitoneal administrationGlycogen synthase kinase-3βNeutrophil accumulation